Expanded Access [11C] Methionine PET Imaging
Trial statusAvailable
Trial phaseNot listed
Trial typeExpanded Access
Biological sexAll
AgeNot listed
SponsorSt. Jude Children's Research Hospital
About this trial
The participants are being asked to get this PET scan because the participants have or may have cancer in the central nervous system (head, neck, or spine), and the investigator and the patient's physician thinks that this scan may provide useful information for the participant's treatment.
Primary Objective
To provide expanded access to L-\[11C\]methionine as a positron-emitting tracer in children and young adults for the positron emission tomography (PET) imaging of neoplasms of the central nervous system (CNS) and head and neck to guide therapeutic management of disease.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
All participants under the care of a SJCRH physician with known or suspected neoplastic disease of the CNS or head and neck are eligible for participation.
No limit on age.
Patients of all genders and all ethnic groups under the care of a SJCRH physician.
Female participants of child-bearing age must not be lactating due to theoretical potential harm to the infant from exposure to radiation.
Disqualifiers
More than six L-[11C]methionine PET scans within the previous 12 months.
Inability or willingness of patient, parent, or guardian to consent.
Trial design
Treatments tested in this trial
L-(11C) methionine
DrugInjected intravenously with 20 mCi/1.7 sq m body surface area of L-\[methyl-11C\]methionine (maximum prescribed dose: 20 mCi).
Treatment groups
No treatment groups listed
Trial outcomes
This trial has no outcomes listed.Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov